Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Ft. Wayne, IN
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Ft. Wayne, IN
Click here to add this to my saved trials
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Detroit, MI
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
mi
from
Allentown, PA
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses
Status: Enrolling
Updated:  1/26/2016
509
mi
from
Graz,
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses
Status: Enrolling
Updated: 1/26/2016
509
mi
from
Graz,
Click here to add this to my saved trials
Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis
A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/28/2016
Sanofi-Aventis Administrave Office
mi
from
Bridgewater, NJ
Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis
A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/28/2016
Sanofi-Aventis Administrave Office
mi
from
Bridgewater, NJ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.
Status: Enrolling
Updated:  1/28/2016
Sanofi-Aventis Administrative Office
mi
from
Bridgewater, NJ
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.
Status: Enrolling
Updated: 1/28/2016
Sanofi-Aventis Administrative Office
mi
from
Bridgewater, NJ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.
Status: Enrolling
Updated:  1/28/2016
Sanofi-aventis Administrative Office
mi
from
Laval,
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.
Status: Enrolling
Updated: 1/28/2016
Sanofi-aventis Administrative Office
mi
from
Laval,
Click here to add this to my saved trials
JC Virus Reactivation in Multiple Sclerosis
JC Virus Reactivation in Multiple Sclerosis
Status: Enrolling
Updated:  1/28/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
JC Virus Reactivation in Multiple Sclerosis
JC Virus Reactivation in Multiple Sclerosis
Status: Enrolling
Updated: 1/28/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Telehealth-Based Exercise Program to Treat Fatigue in MS
Telehealth-Based Exercise Program to Treat Fatigue in MS
Status: Enrolling
Updated:  1/29/2016
VA Puget Sound Health Care System Seattle Division, Seattle, WA
mi
from
Seattle, WA
Telehealth-Based Exercise Program to Treat Fatigue in MS
Telehealth-Based Exercise Program to Treat Fatigue in MS
Status: Enrolling
Updated: 1/29/2016
VA Puget Sound Health Care System Seattle Division, Seattle, WA
mi
from
Seattle, WA
Click here to add this to my saved trials
The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)
The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  2/4/2016
UT Southwestern Medical Center, School of Health Professions
mi
from
Dallas, TX
The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)
The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 2/4/2016
UT Southwestern Medical Center, School of Health Professions
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 110
mi
from
Berkeley, CA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 110
mi
from
Berkeley, CA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 122
mi
from
Long Beach, CA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 122
mi
from
Long Beach, CA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 112
mi
from
Sacramento, CA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 112
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 120
mi
from
San Francisco, CA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 120
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 127
mi
from
Denver, CO
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 127
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 114
mi
from
Maitland, FL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 114
mi
from
Maitland, FL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 135
mi
from
Ormond Beach, FL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 135
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 148
mi
from
Sarasota, FL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 148
mi
from
Sarasota, FL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 147
mi
from
Tampa, FL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 147
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 147
mi
from
Tampa, FL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 147
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 113
mi
from
Northbrook, IL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 113
mi
from
Northbrook, IL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 163
mi
from
Kansas City, KA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 163
mi
from
Kansas City, KA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 142
mi
from
Lenexa, KA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 142
mi
from
Lenexa, KA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 169
mi
from
Lexington, KY
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 169
mi
from
Lexington, KY
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 149
mi
from
Louisville, KY
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 149
mi
from
Louisville, KY
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 159
mi
from
Detroit, MI
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 159
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 167
mi
from
East Lansing, MI
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 167
mi
from
East Lansing, MI
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 137
mi
from
Golden Valley, MN
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 137
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 121
mi
from
Saint Louis, MO
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 121
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 170
mi
from
Las Vegas, NV
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 170
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 162
mi
from
West Long Branch, NJ
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 162
mi
from
West Long Branch, NJ
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 140
mi
from
Johnson City, NY
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 140
mi
from
Johnson City, NY
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 143
mi
from
Raleigh, NC
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 143
mi
from
Raleigh, NC
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 107
mi
from
Akron, OH
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 107
mi
from
Akron, OH
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 164
mi
from
Columbus, OH
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 164
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 145
mi
from
Portland, OR
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 145
mi
from
Portland, OR
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 144
mi
from
Knoxville, TN
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 144
mi
from
Knoxville, TN
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 156
mi
from
Houston, TX
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 156
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 138
mi
from
Lubbock, TX
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 138
mi
from
Lubbock, TX
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 141
mi
from
Kirkland, WA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 141
mi
from
Kirkland, WA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 102
mi
from
Seattle, WA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 102
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 102
mi
from
Seattle, WA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 102
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 165
mi
from
Milwaukee, WI
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 165
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 907
mi
from
Grodno,
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 907
mi
from
Grodno,
Click here to add this to my saved trials
The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis
The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis
Status: Enrolling
Updated:  2/8/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis
The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis
Status: Enrolling
Updated: 2/8/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months
Effect of Teriflunomide (Aubagio®) on Gray Matter Pathology in Multiple Sclerosis: The 12 Months, Prospective, Observational, Single-blinded, Longitudinal Study
Status: Enrolling
Updated:  2/11/2016
Buffalo Neuroimaging Analysis Center
mi
from
Buffalo, NY
Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months
Effect of Teriflunomide (Aubagio®) on Gray Matter Pathology in Multiple Sclerosis: The 12 Months, Prospective, Observational, Single-blinded, Longitudinal Study
Status: Enrolling
Updated: 2/11/2016
Buffalo Neuroimaging Analysis Center
mi
from
Buffalo, NY
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
Yale University
mi
from
New Haven, CT
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
University of Rochester
mi
from
Rochester, NY
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated:  2/21/2016
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
T and B Cell Responses in Autoimmune Diseases
T and B Cell Responses Across Autoimmune Diseases
Status: Enrolling
Updated: 2/21/2016
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
Click here to add this to my saved trials